BIONT - Advanced Pharma Intelligence Blockchain
The biopharmaceutical industry is at a pivotal time in medical discovery, which has enormous potential to further revolutionize the treatment of costly and debilitating diseases like Alzheimer’s, cancer, heart disease, and hepatitis C. Our ability to harness recent scientific advances continues to accelerate, and the potential benefits to patients are becoming clearer.
Much of this progress is attributed to a deeper, molecular-level understanding of all different kinds of diseases. There are more than 7,000 medicines in clinical development around the world right now, more than ever before, and 70% of medicines have the potential to be best-in-class therapies. From 2000 to 2015, this pipeline spawned more than 550 new medicines that were approved by the US Food and Drug Administration (FDA).
A new approach in cancer therapy has the potential to be broadly applicable across a wide range of cancers. Researchers have long understood the metabolism of cancer cells is aggressively ramped up relative to normal cell metabolism, enabling mutated cancer cells to grow exponentially at the expense of healthy surrounding tissue. A number of investigative medicines in clinical development aim to disrupt cancer cell metabolism and impede cell growth.
Some of these medicines target genetic mutations involved in metabolic processes that may be more prevalent in certain cancers. Other cancer metabolism-targeting drugs in development aim to disrupt metabolic functions that occur in most types of cancer. The latter approach works by cutting off the energy supply to cancer cells, causing the cells to die. Medicines targeting cancer metabolism are being explored by researchers to address a range of different cancers, including acute myeloid leukaemia, glioma, lung cancer, pancreatic cancer, breast cancer, and many other blood cancers and solid tumors; these medicines and the many being explored in combination with other cancer therapies offer tremendous hope for patients.
The global Pharma and Biotech Industry ranks high among the most profitable industries in the world. The current market is estimated to grow from $800 Billion USD to $1.2 Trillion by 2022. The market cap of the top 100 pharmaceutical companies is $2.2 Trillion dollars.
Who we are, and what we do
Seasoned team of industry experts based in Zug, Switzerland
Combining industry, pricing, software and trading knowledge
Translate global data into a single non-biased fact-based platform
Seek and identify the highest profitable molecules in clinical development
The Problem
There are 7,000 drugs in development, and 70% of those will be first in class
Only 2 out of 10 drugs match or exceed R&D investment
Evaluate Pharma lowers projections for next 5 years by $390 billion mainly due to pricing pressure
Forecasting is becoming more and more complex due to bio-markers and orphan indications
Trading and stock price volatility has been increasing as a result
The BioNT Token
140,000,000 BioNT Tokens
5-year lock up of unsold tokens
50% of annual software revenues for token buy back
Those tokens will be deleted after buyback
Our Solution and Development Roadmap to Drug Discovery
The global drug pricing platform is designed to retrieve drug prices from global disparate sources. Sources are both public/government and private sources. The initial focus will be Oncology and Orphan diseases, paving the way for price setting and trends for new combination therapies.
Epidemiology data bank will store patient treatment pathways for key diseases, the data bank will also be populated with patient numbers to link new molecules to market potential.
Tracking both historical and upcoming outcomes and approvals will enable the platform to predict and report the sensitivity analysis. The key data blocks linked with historical data, will allow Advanced Pharma Intelligence not only the ability to deliver analysis to front end clients, but also the algorithm to predict outcomes based on Phase I and Phase II outcomes data
Development Road Map
The development and commercialization of the three core projects will be subject to the level of funding secured. The timeline outlined for development and delivery seeks to maximize both development and commercialization.
The X-APP will be detailed post development and prior to commercialization. The APP will provide a hub to link and retrieve global data for the platforms described above.
Investment & Allocation – Detail
- Development of trading Platform - 25%
- Development of Drug Forecasting Platform - 20%
- Global Marketing & Sales Phase 1 - 10%
- Global Marketing & Sales Phase 2 - 10%
- Merge Pricing and Forecasting Platform - 10%
- Enhancement of, and Commercialization Beta Pricing Platform - 10%
- Team Allocation - 10%
- Legal - 5%
ICO Details
Token ICO starting 21-08-2017, at 08.08pm UTC, until sold out or till end of ICO period.
1st + 2nd weeks 20% additional tokens
3rd week 15% additional tokens
4th week 10% additional tokens
5th week 5% additional tokens
6th/9th week, finishing 23-10-2017, at 08.08pm UTC, no bonus tokens
Token Name: BioNT
Fixed Price: 300 BioNT per ETH
Issuing Entity: Advanced Pharma Intelligence GmbH
Jurisdiction of Issuance: Switzerland
Our Team
SABINE ALBRECHT - CEO & Co-FounderOver 16 years of experience in the biotech sector
PATRICK RANZIJN - CFO/InvestorOver 25 years in finance and investment trading
JAS DOSANJH - Co-FounderOver 25 years of experience, cumulating 15 years within the biotech sector
SAM BROTHERTON - Software Architect & Engineer, and Data ScientistSoftware Engineer, Data Scientist and Natural Language Processing
GAUTAM BAJEKAL - Sales & Marketing Life Sciences Software, AdvisorSales & Marketing Life Sciences Software
LAURIAN RUSSO - Risk Manager, Trading OperationsLeading software development in both financials and pharmaceuticals
JEAN FABRICE FARIA - Securities TradersDeep knowledge of trading and risk management and a highly quantitative background, with experience in building pricing, risk and analytics platforms besides managing and operating trading desks
IONUT DUMITRU - Web and Blockchain, AdvisorVast experience in building high traffic websites and applications
MARCEL KLEENE - AdvisorDeep knowledge of cryptocurrencies and finance
Links
Whitepaper
Official Website
Announcement
Telegram
Slack